Introduction
Alzheimer's disease is the most common neurodegenerative disorder. The accumulation of amyloid-b in the brain is one of the earliest pathological hallmarks of the disease and is considered to play a key role in Alzheimer's disease pathogenesis. Recent developments in molecular imaging have made it possible to visualize the fibrillar amyloid-b plaques in the brains of living patients with Alzheimer's disease, using PET (Nordberg et al., 2010; Reiman and Jagust, 2012) . New criteria for the early diagnosis of Alzheimer's disease suggest the combined use of PET amyloid imaging and CSF biomarkers (Dubois et al., 2010; McKhann et al., 2011 , Sperling et al., 2011 .
11
C-Pittsburgh compound B (PIB) is a widely studied amyloid tracer that detects fibrillar amyloid-b with high accuracy (Klunk et al., 2004; Nordberg et al., 2010; Rowe and Villemagne, 2011) . PET has demonstrated high PIB retention in cortical brain regions of patients with Alzheimer's disease (Klunk et al., 2004; Engler et al., 2006; Rowe et al., 2010) and patients with mild cognitive impairment that later converted to Alzheimer's disease (Kemppainen et al., 2007; Forsberg et al., 2008; Jack et al., 2009; Nordberg et al., 2013) . Moreover, 10-30% of cognitively normal adults demonstrate a high presence of amyloid-b plaques in the brain according to 11 C-PIB measurements, and the prevalence increases with age (Mintun et al., 2006; Pike et al., 2007; Rowe et al., 2007; Aizenstein et al., 2008; Morris et al., 2010; Villemagne et al., 2011 Villemagne et al., , 2013 Nordberg et al., 2013) . However, although amyloid PET imaging has contributed to a better understanding of amyloid-b processes in vivo, the molecular mechanisms and binding properties of amyloid tracers in the brains of patients with Alzheimer's disease and cognitively normal adults are not yet fully understood.
The amyloid PET tracers developed to date belong to various chemical classes, including thioflavin T ( 11 C-PIB, Klunk et al., 2004; 18 F-flutemetamol, Nelissen et al., 2009; 11 C-AZD2184, Nyberg et al., 2009 ), stilbenes ( 18 F-AV-45, Clark et al., 2011 18 F-AV-1, Rowe et al., 2008; and 11 C-SB-13, Verhoeff et al., 2004) , benzoxazoles ( 11 C-BF-227, Kudo et al., 2007; 18 F-BF-227, Harada et al., 2013) , aminonaphthalenes ( 18 F-FDDNP, Shoghi-Jadid et al., 2002) and benzofurans ( 18 F-AZD4694, Cselenyi et al., 2012) . The fact that different amyloid PET tracers emanate from different chemical classes may suggest that in addition to similarities, they may also show dissimilarities in binding properties to fibrillar amyloid-b and also bind to other forms of amyloid-bs. The extent of possible differences between different amyloid tracers in binding profiles and detection of fibrillar amyloid-b deposits in the Alzheimer's disease brain has not been thoroughly investigated. (Johnson et al., 2013) .
In vivo PET evidence of 11 C-PIB retention strongly correlates with quantitatively measured amyloid-b levels in Alzheimer's disease brains at autopsy (Ikonomovic et al., 2008; Kadir et al., 2011) . Similarly, a close relationship between in vivo amyloid tracer retention and histopathological assessment of amyloid pathology has been reported in brain biopsies for 11 C-PIB, 18 F-flutemetamol (Leinonen et al., 2008 (Leinonen et al., , 2013 and at autopsy for 11 C-PIB (Driscoll et al., 2012) , ( 18 F-florbetapir) (Clark et al., 2011 , (Wolk et al., 2011) .
The aim of this study was to characterize the regional 3 H-PIB binding properties in Alzheimer's disease and cognitively normal control post-mortem brain tissues and to compare the corresponding detection of fibrillar amyloid-b pathology with that of amyloid PET tracers BTA-1, AV-1, AV-45, BF-227 and FDDNP in Alzheimer's disease brain tissue. 
Material and methods

Tracers
Statistical analysis
Data were analysed using GraphPad Prism version 5.0. Table 2) . Analysis of total amyloid-b 40 and amyloid-b 42 levels quantified by ELISA revealed significant higher amyloid-b levels in the frontal cortex compared with hippocampus (P 5 0.05) ( Table 3) . 3 H-PIB binding performed in the same brain tissue samples as the amyloid-b ELISA measurements showed a 5-fold difference in 3 H-PIB binding whereas a 10-fold difference in amyloid-b 40 + 42 levels in the frontal cortex compared with hippocampus (Table 3) H-PIB binding sites in the Alzheimer's disease brain, homogenates from the frontal cortices and hippocampi of five Alzheimer's disease brains were incubated with a wider range of 3 H-PIB concentrations (0.01-300 nM; Table 2 ).
Supplementary Fig. 1 shows the saturation binding curve (0.01-300 nM) in the frontal cortex of one Alzheimer's disease brain (78 years). In addition to the high-affinity site described above, the Scatchard plots revealed the presence of low-affinity 3 H-PIB binding sites in the frontal cortices (mean K d2 :
133 AE 30 nM) and the hippocampi (mean K d2 : 181 AE 132 nM) of the five Alzheimer's disease brains (Table 2) . No significant differences in dissociation constants for the high-and low-affinity sites (K d1 and K d2 ) were observed between the frontal cortex and the hippocampus (Table 2 ). The B max value for the high-affinity site (B max1 ), but not the low-affinity site (B max2 ), in the frontal cortex was significantly higher than that in the hippocampus.
Characterization of 3 H-Pittsburgh compound B binding sites in control frontal cortex and hippocampus
Saturation binding studies with 3 H-PIB 0.1 to 300 nM were also performed in the frontal cortices and hippocampi of five control brains (from patients aged 54-87 years). Analysis revealed 3 H-PIB high-affinity binding (similar to that seen in the Alzheimer's disease frontal cortex; Supplementary Fig. 2A and B) in the frontal cortex of only one (87-year-old) control subject, with a K d1 of 1.6 nM and B max1 of 309 pmol/g. All three control brains tissues that incubated with wider range (0.1-300 nM) of 3 H-PIB showed evidence of a low-affinity site in the frontal cortex with comparable K d2 values (191 AE 70 nM) to those in Alzheimer's disease brains (133 AE 30 nM) ( Supplementary Fig. 2C and D) . In the hippocampus of the 87-year-old control subject, only a low-affinity binding site was detected (K d2 : 136 nM; B max2 : 2788 pmol/g). The presence of some amyloid-b 42 plaques in the frontal cortex of this 87-year-old control brain was confirmed by (Table 3 ).
Regional distribution of 3 H-Pittsburgh compound B binding in Alzheimer's disease and control brain tissue
The distribution of 3 H-PIB (1 nM) binding was studied in the frontal and parietal cortices, caudate nuclei, hippocampi and cerebella of 23 patients with Alzheimer's disease (mean age 70.5 AE 9.0 years) and 20 normal control subjects (mean age 73.8 AE 11.6 years).
3 H-PIB binding in Alzheimer's disease brains was highest in the frontal and parietal cortices, followed in order by the caudate nucleus, hippocampus and cerebellum (Fig. 2) .
3 H-PIB binding was significantly higher in the frontal and parietal cortices (P 5 0.001), hippocampi (P 5 0.01) and caudate nuclei (P 5 0.001) of Alzheimer's disease brains than in age-matched controls (Fig. 2) . Although a significant difference in 3 H-PIB binding was observed between controls versus early-onset Alzheimer's disease and control versus late-onset Alzheimer's disease, no significant difference was found between early-onset and late-onset Alzheimer's disease (Fig. 2) . No significant difference in binding was observed between Alzheimer's disease APOE "4 (n = 16) and non-"4 (n = 7) carriers (data not shown). and B max2 = maximum number of high-and low-affinity binding sites; % High = percentage of high-affinity binding sites; K d1 and K d2 = high-and low-affinity site dissociation constants; % Low = percentage of low-affinity binding sites; R 2 = extent of the fit to the nonlinear regression two-binding-site model; SD = standard deviation.
Significant differences between frontal cortex and hippocampus (paired t-test; n = 5) are indicated by *P 5 0.05 and **P 5 0.01. Analysis of the displacement binding results demonstrated the presence of two of three possible binding sites for all the unlabelled amyloid ligands except FDDNP. The affinity for the sites (K i1 , K i2 or K i3 ) for these ligands followed the rank order BTA-1 (K i1 : 0.2 nM, K i2 : 70 nM) 4AV-45 (K i1 : 1.0 nM, K i2 : 65 nM) 4 AV-1 (K i1 : 1.8 nM, K i2 : 53 nM)4 BF-227 (K i1 : 0.3 nM, K i3 : 311 nM) (Fig. 3A-D) . The proportions of high-affinity binding sites were 88%, 90% and 84% for BTA-1, AV-45 and AV-1, respectively (summarized in Fig. 3A-C) . The proportion of high-affinity binding sites for BF-227 was only 17% (Fig. 3D) ; most of the binding was to the 311 nM affinity site (83%). No K i value was obtained for FDDNP because 3 H-PIB binding was displaced by 550% (Fig. 3E) . Additional autoradiography binding assays were performed in frontal cortex sections from four of the Alzheimer's disease and four of the control brains that were evaluated in the homogenate binding assays. These showed that 3 H-PIB binding was completely blocked in the presence of 1 mM BTA-1, AV-45 and AV-1, whereas addition of 1 mM BF-227 or 1mM FDDNP displaced only 70% and 40% of 3 H-PIB binding, respectively ( Supplementary Fig. 3 ).
Discussion
Advances in amyloid PET imaging have already had an impact on the understanding of the time course of Alzheimer's disease pathophysiology (Jack et al., 2013; Nordberg et al., 2010 Nordberg et al., , 2011 , as well as the development of biomarkers for early diagnosis, and their use in evaluation of anti-amyloid clinical trials. Recent ongoing debate on amyloid PET imaging has raised questions with regard to the binding properties of different amyloid ligands, their sensitivity and their specificity in reflecting amyloid-b pathology in the Alzheimer's disease brain (Moghbel et al., 2012; Villemagne et al., 2012a) . This study provides detailed characterization of PIB binding in Alzheimer's disease and normal control post-mortem brain tissue, as well as a comparison of current available amyloid ligands. The study demonstrated a regional distribution of 3 H-PIB binding in the rank order frontal cortex, parietal cortex, caudate nucleus and hippocampus, which is consistent with in vivo 11 C-PIB PET studies in patients with Alzheimer's disease (Klunk et al., 2004; Mintun et al., 2006; Kemppainen et al., 2006; Rowe et al., 2010; Nordberg et al., 2013) . This was also our rationale for focusing on one region as the frontal cortex with high amyloid and hippocampus with low amyloid load in the characterization of 3 H-PIB binding in the brain.
We demonstrated the presence of both high-and low-affinity binding sites in the frontal cortex and hippocampus in patients with Alzheimer's disease, and report the presence of a low-affinity site in the cognitively normal control subjects. We also demonstrated that PIB, AV-45 and AV-1 share a common high-affinity binding site with amyloid-b in Alzheimer's disease brain, whereas BF-227 shows lower affinity, and FDDNP has a different binding profile.
The observation of two 3 H-PIB binding sites in Alzheimer's disease frontal cortex in this study is in agreement with an earlier report by Klunk et al. (2005) . To the best of our knowledge, our study is the first to identify the presence of both high-and lowaffinity PIB binding sites in the Alzheimer's disease hippocampus.
We measured a 30-fold difference in affinity between the two binding sites in both the frontal cortex and the hippocampus, but no difference in affinity for the two sites between these two regions. The proportion of high-affinity to low-affinity sites was This could be attributed to the time course of amyloid accumulation, as it has been observed that the proportion of cognitively normal control subjects demonstrating high amyloid levels in the brain increases with age, and could have implications for antiamyloid-b clinical trials in cognitively normal adults (Selkoe, 2012) . Because in vivo PET imaging is performed at nanomolar tracer concentrations, low-affinity PIB binding sites cannot be visualized by this method and studies using other techniques are warranted for further detection and characterization of these low-affinity binding sites in the human brain. The presence of low-affinity binding sites could be of mechanistic importance for aggregation processes involving seeding and the progressive development of amyloid-b pathology in the brain, including the occurrence of other smaller forms of amyloid-b such as oligomer assemblies.
In vitro binding studies in fresh tissue brain homogenates have higher sensitivity to detect multiple binding sites than in vivo studies since a much broader range of concentrations of both labelled amyloid radiotracer as well a wider concentration range of competing substances can be used in displacement studies. In vitro binding studies thus allow detection of binding types with different properties. As the concentration range is broader, high, intermediate and low affinity binding sites can be detected. The in vivo PET technique uses amyloid tracer concentrations in a much narrow concentrations range (1-10 nM) and due to risk of toxicity reactions displacement with increasing higher concentrations of unlabelled amyloid tracers have not been able to be performed. Thus so far no saturation studies demonstrating saturation of labelled amyloid binding sites by unlabelled compounds have been able to be performed by PET for any amyloid tracer in humans with the exception of the in vivo displacement performed using non-steroidal anti-inflammatory drugs and 18 F-FDDNP (Agdeppa et al., 2003) .
In the present study the competition assays in tissue homogenates were performed in frontal cortical tissue since frontal cortex shows high 3 H-PIB binding, which allows competing reduction in the binding with different agents. The hippocampus was not included in these experiments because the 3 H-binding in this brain region opposite to the frontal cortex is low and it is technically much more difficult to obtain reliable displacement values due to larger variation in displacement data.
In vitro binding studies with thioflavin-derived compounds and synthetic amyloid-b polymers have reported that these ligands bind to three classes of binding sites on the amyloid-b fibrils Ye et al., 2005) . This included binding with very high affinity (K d % low nM) to a low-capacity site (BS3), as well as binding (K d % 100 nM) to either one of two additional adjacent or partially overlapping high-capacity binding sites (BS1, BS2) on the amyloid-b 1-40 polymer Ye et al., 2005) .
Based on the saturation and displacement assay results in our study, we propose a multiple binding site model (binding sites 1, 2 and 3) for the tested amyloid ligands, as illustrated in Fig. 5F . Competition studies with 3 H-PIB revealed that AV-1, AV-45 and BTA-1 bound mainly to the high-affinity ($1 nM) PIB binding site (binding site 1). This is in agreement with earlier saturation binding studies on individual ligands in human brain tissues (Klunk et al., 2003; Zhang et al., 2005; Choi et al., 2009; Kung et al., 2010; Fodero-Tavoletti et al., 2012) . Furthermore, these amyloid ligands also displaced 3 H-PIB from the low-affinity binding site 2 (K i 5 100 nM). From PET imaging studies in patients with Alzheimer's disease it is known that 11 C-BF-227 is less extensively retained in the cortex in patients with Alzheimer's disease than 11 C-PIB (Kudo et al., 2007; Furukawa et al., 2010; Shao et al., 2010) . These observations corroborate our finding that BF-227 binding was only 16% to the high-affinity binding site 1, whereas PIB binding to this site was 480%. Instead, a higher proportion of BF-227 binding was with a different low-affinity site from binding sites 1 and 2 (K i3 311 nM; binding site 3) (Fig. 3F) . The displacement of only 40% of 3 H-PIB binding by FDDNP suggests that this ligand has a binding profile that differs from that of the other amyloid ligands (Agdeppa et al., 2001; Thompson et al., 2009) . In earlier studies, FDDNP was reported to bind to neurofibrillary tangles in addition to amyloid-b plaques, and it has been suggested that it interacts with the binding of non-steroidal anti-inflammatory drugs (Agdeppa et al., 2001; Thompson et al., 2009; Petric et al., 2012) and also that it binds to a different site on the amyloid-b fibrils from those of PIB (Raman et al., 2009; Kung et al., 2010; Wu et al., 2011) . Moreover, a different regional distribution pattern and lower signal range has been observed in vivo with 18 F-FDDNP compared with 11 C-PIB (Shoghi-Jadid et al., 2002; Shin et al., 2008; Tolboom et al., 2009) .
One limitation of our study is that only radiolabelled PIB was used in the comparative studies of binding with other amyloid ligands. There is a possibility that, if they had been radiolabelled, these amyloid ligands may have enabled the detection of additional binding sites on amyloid-b fibrils that were not readily recognized by 3 H-PIB, and could thus have shown different binding profiles. Additional studies in brain tissue homogenates from carriers of autosomal dominant Alzheimer's disease may most probably provide further insight into difference in amyloid binding sites pattern. In the present study the frontal cortex was chosen as region with high amyloid load. For further studies precuneus would be of great interest with its early high binding of amyloid tracers in course of disease and its correlation with cognitive function in normal subjects (Rosenberg et al., 2013) . It will be important in future studies to consider the elucidation of possible binding interactions, other than those on amyloid-b fibrils, between amyloid ligands and other endogenous proteins or receptors. In support of this suggestion, we have recently reported a relationship between high-affinity PIB binding sites and 7 nicotinic receptors in post-mortem Alzheimer's disease brain studies (Lilja et al., 2011; Ni et al., 2013) . Interactions such as these may be intrinsically linked to the neurodegenerative changes in the Alzheimer's disease brain and could necessitate the development of better imaging agents in the future to further advance our understanding of the disease at the molecular level.
In summary, this study indicates the presence of multiple PIB binding sites (high-and low-affinity) in Alzheimer's disease and control brains with confirmed amyloid pathology. From competition studies we propose a multiple site model where PIB, AV-45 (florbetapir) and AV-1 (florbetaben) share similar binding to a nanomolar high affinity site (site 1) and that these amyloid ligands can be used in a comparable and reliable manner to assess brain amyloid density. A somewhat different binding pattern is observed for BF-227 and FDDNP with preference for sites 3 and 2, respectively. Detailed studies of binding characteristics for amyloid PET tracers may provide valuable information for a further understanding of Alzheimer's disease pathology.
